Shares of Cincor Pharma Inc. (NASDAQ:CINC) took a serious hit on top-line findings from the completed phase II Halo study with once-daily oral baxdrostat, but the clinical program with the aldosterone synthase inhibitor remains on track, and an NDA submission is targeted for 2025. The stock closed at $14.11, down $12.42, or 46.8% after Waltham, Mass.-based Cincor informed Wall Street that results from Halo, which enrolled patients taking as many as two blood pressure medications at the maximally tolerated doses without satisfactory results, missed statistical significance on its primary endpoint evaluating change from baseline in mean seated systolic blood pressure in the intent-to-treat population, which included 249 patients.